Fennec Pharmaceuticals (TSE:FRX) Upgraded at Stephens

Stephens upgraded shares of Fennec Pharmaceuticals (TSE:FRX) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

Fennec Pharmaceuticals Price Performance

Shares of TSE:FRX opened at C$6.50 on Monday. The business has a 50-day simple moving average of C$6.41 and a two-hundred day simple moving average of C$8.03. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The firm has a market cap of C$177.84 million, a price-to-earnings ratio of 66.50 and a beta of 0.25. Fennec Pharmaceuticals has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.43.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.